Fresenius
Also known as: EUROHEAD | FRESENIUS | Fresenius AG | Fresenius Biotech North America | Fresenius Hemocare | Fresenius Kabi | FRESENIUS KABI | Fresenius Kabi Austria GmbH, Graz | Fresenius Kabi Japan | FRESENIUS KABI ONCOL | Fresenius Kabi Oncology Ltd. | Fresenius Kabi SwissBioSim GmbH | FRESENIUS KABI USA | Fresenius Kabi USA, LLC | FRESENIUS KABI USA LLC | FRESENIUS MEDCL | Fresenius Medical Care Deutschland GmbH | Fresenius Medical Care Korea | Fresenius Medical Care North America | Fresienius Kabi HK Ltd | Randolph Quinn | VIFOR FRESENIUS | Vifor Fresenius Medical Care Renal Pharma | Xenios AG
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2003First marketed drug
Nov 19, 1948First NDA
Nov 19, 1948Last known activity
Mar 30, 2026
Timeline
1910s
- Jan 1, 1912
Fresenius— Founded
1950s
- Mar 11, 1955
chloroprocaine— NDA Organization
1990s
- Jul 7, 1997
Spectra Clinical Research— Acquired
2010s
- Apr 3, 2015
moxifloxacin— NDA Secondary Org
- Aug 7, 2017
NxStage Medical— Acquired
2020s
- Apr 5, 2024
mitomycin— Marketing Organization
Drugs by trial phase (83 distinct, 92 trials)
Phase 4 (25 own, 0 via acquisition)
Phase 3 (17 own, 4 via acquisition)
Phase 2 (17 own, 0 via acquisition)
Phase 1 (10 own, 0 via acquisition)
Other trials (10 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acute Kidney Injury
- Anemia
- Anemia, Iron-Deficiency
- Arthritis
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Ascites
- Brain Injuries
- Brain Injuries, Traumatic
- Breast Neoplasms
- Burns
- Carcinoma, Ovarian Epithelial
- Child Nutrition Disorders
- Cholestasis
- Compartment Syndromes
- Critical Illness
- Crohn Disease
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Digestive System Neoplasms
- Emergencies
- Femoral Fractures
- Fractures, Bone
- Gastrointestinal Neoplasms
- Graft vs Host Disease
- Hemorrhage
- Hidradenitis
- Hidradenitis Suppurativa
- Hip Fractures
- Hyperphosphatemia
- Hypertension
- Hypoglycemia
- Hypotension
- Hypovolemia
- Inflammation
- Intra-Abdominal Hypertension
- Intraoperative Complications
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Myeloid, Acute
- Liver Diseases
- Malnutrition
- Ovarian Neoplasms
- Postoperative Complications
- Psoriasis
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Sepsis
- Short Bowel Syndrome
- Spondylitis
- Spondylitis, Ankylosing
- Subarachnoid Hemorrhage
- Systemic Inflammatory Response Syndrome
- Toxemia
- Uveitis
- Wounds and Injuries
Marketed drugs (211)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT07254637CollaboratorPhase 2Nov 30, 2025
- NCT06593392Lead sponsorPhase 2Jan 31, 2025
- NCT06049680Lead sponsorPhase 4Sep 30, 2023
- NCT05885763Lead sponsorPhase 1Jun 26, 2023
- NCT05885737Lead sponsorPhase 3May 30, 2023
- NCT05681429CollaboratorN/AJan 1, 2023
- NCT05302531CollaboratorPhase 1Apr 4, 2022
- NCT05257031Lead sponsorPhase 3Feb 12, 2022
- NCT05136664Lead sponsorPhase 3Dec 31, 2021
- NCT05100212CollaboratorPhase 2Nov 30, 2021
- NCT04934072Lead sponsorPhase 3Jul 5, 2021
- NCT04474886CollaboratorN/ANov 15, 2020
- NCT04512001Lead sponsorPhase 3Jul 27, 2020
- NCT04099108CollaboratorN/AJul 1, 2020
- NCT04250298CollaboratorPhase 4Nov 13, 2019
Details
- Founded
- Frankfurt, DE Jan 1, 1912
- First NDA
- Nov 19, 1948
- Last known activity
- Mar 30, 2026
Designations held
- Orphan drug
- Priority review